In murine models, GLP-1RAs have been shown to reduce the incidence of HCC associated with NASH (Kojima et al., 2020)
has provided consultation to Eisai, Biogen, Lilly, Roche, Genentech, Bolden, Novo Nordisk, Prothena, Acumen Pharmaceuticals, Labcorp, Alector, Corium, Kisbee, Neurophet, Icometrix and AbbVie
The Medicare GLP-1 Bridge (launching July 1, 2026, through December 31, 2027) provides weight-loss access to Wegovy at a fixed $50 per month copay outside Part D this $50 does not count toward the deductible, TrOOP, or the $2,100 OOP cap
Zepbound vs Mounjaro for Weight Loss Results A clinical trial for Zepbound and Mounjaro that involved two randomised, placebo-controlled, 72-week-long studies in over 3,400 adults with obesity revealed interesting findings